Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)

Revenue by Product

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Active Pharmaceutical Ingredients and Intermediates - Cardiovascular	432.01M
Active Pharmaceutical Ingredients and Intermediates - Cardiovascular Growth	43.81%
Finished Drugs	220.02M
Finished Drugs Growth	144.87%
Active Pharmaceutical Ingredients and Intermediates - Anti-Tumor	211.73M
Active Pharmaceutical Ingredients and Intermediates - Anti-Tumor Growth	-13.31%
Active Pharmaceutical Ingredients and Intermediates - Respiratory System	190.72M
Active Pharmaceutical Ingredients and Intermediates - Respiratory System Growth	16.80%
Active Pharmaceutical Ingredients and Intermediates - Women's Health	126.31M
Active Pharmaceutical Ingredients and Intermediates - Women's Health Growth	-33.11%
Active Pharmaceutical Ingredients and Intermediates - Trade Products	111.39M
Active Pharmaceutical Ingredients and Intermediates - Trade Products Growth	5.81%
Active Pharmaceutical Ingredients and Intermediates - Other	86.93M
Active Pharmaceutical Ingredients and Intermediates - Other Growth	24.28%
Active Pharmaceutical Ingredients and Intermediates - Nervous System	68.09M
Active Pharmaceutical Ingredients and Intermediates - Nervous System Growth	-7.46%
Active Pharmaceutical Ingredients and Intermediates - Anti-infection	24.86M
Active Pharmaceutical Ingredients and Intermediates - Anti-infection Growth	34.49%
Other	3.67M
Other Growth	-57.28%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Overseas	1.15B
Overseas Growth	4.64%
China	330.45M
China Growth	96.64%